NeuroBo Pharmaceuticals | 424B3: Prospectus
NeuroBo Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation
NeuroBo Pharmaceuticals | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-10% Owner DONG-A ST CO., LTD
NeuroBo Pharmaceuticals | D: Filing D
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner DONG-A ST CO., LTD
NeuroBo Pharmaceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Dong-A ST Co., Ltd.(53.5%)
NeuroBo Pharmaceuticals | 424B5: Prospectus
NeuroBo Pharmaceuticals | 8-K: Entered into a Securities Purchase Agreement
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals' Da-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, And Lipid-Lowering Effects Compared to Survodutide, In Pre-Clinical Models
NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Salsbury Michael
NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GROVES JASON L
NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director KOVEN ANDREW I
NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Glickman Mark A
NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director STRICKLAND D GORDON
NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Tursi James Patrick
NeuroBo Pharmaceuticals | 8-K: Poll Results of NeuroBo Pharmaceuticals Meeting
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals’ DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
NeuroBo Pharmaceuticals | 10-Q: Quarterly report
No Data